Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors

Print this page

Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors

To evaluate preliminary signals of potential anti-tumor activity of MK-3475
in subjects with a given a histopathologic type of PD-L1 positive advanced solid tumor based on RECIST 1.1 as determined by the investigator in specific tumor indications

Protocol Number051304
Principal InvestigatorJanice Mehnert
PhasePhase I/II
ScopeNational
Applicable Disease SitesOvary
Prostate
Rectum
Lung
Therapies InvolvedChemotherapy single agent systemic
Drugs InvolvedMK-3475
Participating InstitutionsRutgers Cancer Institute of New Jersey

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.